Pharmacogenomics and Personalized Medicine in Alzheimer’s Disease

摘要: Alzheimer’s disease (AD) and related dementias, neurodegenerative disorders accompanied by progressive deterioration of cognitive capacity, every-day behavior abilities, integrity brain tissue, present an ever-growing, worldwide dilemma due to aging populations confronted a neuropathology. The “amyloid cascade hypothesis,” that pathophysiology is driven the ever-increasing burden β-amyloid in brains afflicted patients, involves poorly understood orchestration encompassing multitudes enzymes signaling pathways arranged vast diverse arrays cellular processes, vascular considerations all which are under control predictive genes susceptibility describe genetic x environmental epigenetic interactions. Genetic aspects these intricacies pharmacogenomics implicated several neurotransmitter pathways, circuits regional developments, metabolism reinforce growing requirements for personalized medicine. search individual-based medication, addition genomic assay biomarker identity, seeks establish “reregulation” destructive understanding application Aβ-linked immunotherapy, initiation formulation pharmacogenetic/pharmacogenomics principles methodologies, emergence role apolipoprotein (APOE) therapeutic endeavor, assessment treatment behavioral psychological symptoms, therapies focused upon frontotemporal dementia, interventions centered around instrumental activities daily activities.